Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.

被引：0
|
作者：
Ravandi, Farhad
Carraway, Hetty E.
Taningco, Lilia
Laille, Eric
Gong, Jing
Prebet, Thomas
De Menezes, Daniel Lopes
Wei, Andrew H.
机构：
[1] Univ Texas MD derson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Taussig Canc Inst, Cleveland Clin, Leukemia Program, Cleveland, OH USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Peter MacCallum Canc Ctr, Melbourne, VIC, Australia
[5] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7068
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [32] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
    Yu, Hong
    Wang, Chaomeng
    Lei, Yingying
    Li, Lijuan
    Wang, Huaquan
    Wang, Guojin
    Xing, Limin
    Guan, Jing
    Song, Jia
    Wu, Yuhong
    Liu, Hong
    Qu, Wen
    Wang, Xiaoming
    Shao, Zonghong
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [33] TRIAL IN PROGRESS: A PHASE 1B STUDY OF ALRIZOMADLIN, ALONE OR PLUS 5-AZACITIDINE OR CYTARABINE, IN PTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND RELAPSED HIGHER-RISK MYELODYSPLASTIC SYNDROME
    Zhai, Yifan
    Wang, Jianxiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A478 - A478
  • [34] Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek A.
    Saliba, Antoine N.
    Torghabeh, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Yi, Cecilia Arana
    Tefferi, Ayalew
    Gangat, Naseema
    HAEMATOLOGICA, 2024, 109 (08) : 2706 - 2710
  • [35] Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
    Gibson, Amber
    Dickson, Samantha
    McCall, David
    Garcia, Miriam
    Connors, Jeremy
    He, Jiasen
    Roth, Michael
    Nunez, Cesar
    Cuglievan, Branko
    PEDIATRIC BLOOD & CANCER, 2024,
  • [36] Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
    Garcia-Manero, Guillermo
    Abaza, Yasmin
    Takahashi, Koichi
    Medeiros, Bruno C.
    Arellano, Martha
    Khaled, Samer K.
    Patnaik, Mrinal
    Odenike, Olatoyosi
    Sayar, Hamid
    Tummala, Mohan
    Patel, Prapti
    Maness-Harris, Lori
    Stuart, Robert
    Traer, Elie
    Karamlou, Kasra
    Yacoub, Abdulraheem
    Ghalie, Richard
    Giorgino, Ruben
    Atallah, Ehab
    BLOOD ADVANCES, 2019, 3 (04) : 508 - 518
  • [37] Polatuzumab vedotin plus obinutuzumab plus venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
    Bannerji, Rajat
    Yuen, Sam
    Phillips, Tycel Jovelle
    Arthur, Christopher
    Isufi, Iris
    Marlton, Paula
    Seymour, John Francis
    Corradini, Paolo
    Molinari, Annalia
    Gritti, Giuseppe
    Emmons, Robert
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
    DiNardo, Courtney D.
    Lachowiez, Curtis A.
    Takahashi, Koichi
    Loghavi, Sanam
    Xiao, Lianchun
    Kadia, Tapan
    Daver, Naval
    Adeoti, Maria
    Short, Nicholas J.
    Sasaki, Koji
    Wang, Sa
    Borthakur, Gautam
    Issa, Ghayas
    Maiti, Abhishek
    Alvarado, Yesid
    Pemmaraju, Naveen
    Bravo, Guillermo Montalban
    Masarova, Lucia
    Yilmaz, Musa
    Jain, Nitin
    Andreeff, Michael
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kornblau, Steven
    Ravandi, Farhad
    Konopleva, Marina Y.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) : 2768 - +
  • [39] A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
    Bang, Su-Yeon
    Park, Silvia
    Kwag, Daehun
    Lee, Jong Hyuk
    Min, Gi-June
    Park, Sung-Soo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    Kim, Hee-Je
    CANCERS, 2023, 15 (06)
  • [40] Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia
    Mims, Alice
    Xie, Zhuoer
    Potluri, Ravi
    Rotter, David
    Chevli, Manoj
    Prebet, Thomas
    Gaugler, Lona
    Strocchia, Maria
    Vasconcelos, Alberto
    Sieluk, Jan
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 479 - 487
12345